The Cancer Letter

Sections

Personal tools

You are here: Home → The Clinical Cancer Letter Archive → February 2010, Vol. 33 No. 2

cancer_news: Etubics Enters Phase I Cancer Clinical Trials Focused On Colorectal Cancer; Biology, Computer Science Combine Efforts To Fight Cancer; NCCN Receives $4 Million In Oncology Research Funding From GlaxoSmithKline; New Surgery Without Incisions Shows Promise For Prostate Cancer Treatment; Abraxis BioScience And Specialised Therapeutics Announce Approval To Market ABRAXANE For Metastatic Breast Cancer In New Zealand; see more…

Document Actions

February 2010, Vol. 33 No. 2

by Kirsten Goldberg — last modified 2010-02-23 22:19

Breast Cancer Survivors Who Take Aspirin Have 50% Reduced Risk Of Metastasis, Breast Cancer Death. Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC. Symptoms Not Useful For Early-Stage Ovarian Cancer Detection.

Welcome. Please log in to download the newsletter if you are a subscriber. You can use the log in box in the right column. If not a subscriber, please subscribe or get a one day pass using the links below.

Click here to subscribe

Click here to get a one day pass

Log in: Login Name

Password

Cookies are not enabled. You must enable cookies before you can log in.; Forgot your password?

Google Ad Links

Google Ads

This site conforms to the following standards: